Zlatko Rihter appointed new CEO of Mölnlycke
Zlatko Rihter has been appointed President and CEO of the medical solutions company, Mölnlycke Health Care AB.
Zlatko Rihter is a Swedish citizen and currently President and CEO of Sweden-based CellaVision, a world-leading provider of digital solutions for medical microscopy in the field of hematology, listed on Nasdaq Nordic.
'We are very pleased to see Zlatko Rihter joining Mölnlycke. He brings solid knowledge from the medtech industry and a strong track record of growth based on innovation and customer focus,' says Gunnar Brock, Chairman of Mölnlycke.
Zlatko Rither has extensive experience from the healthcare sector after having spent more than 20 years within the industry. Prior to joining CellaVision in 2015, Zlatko Rither held the position as EVP Sales & Marketing at ORIGIO, as well as President GBU Chronic at Gambro and Director Patient Handling Product Division at ArjoHuntleigh.
Zlatko Rihter’s starting date as President and CEO of Mölnlycke is still to be confirmed.
'I am very honoured to join Mölnlycke, a company I have admired over the years. I believe that with my industry experience and various operational roles in different companies I can contribute to the success of Mölnlycke,' says Zladko Rihter.
For further information, please contact Jenny Johansson, Corporate Communications,
+46 739 41 29 23, or firstname.lastname@example.org
Mölnlycke is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. We design and supply products and solutions for use in wound treatment, pressure ulcer and infection prevention and surgery.
Mölnlycke employs around 7,800 people. The company headquarters are in Gothenburg, Sweden and we operate in more than 100 countries worldwide. Since 2007, the company is part of Investor AB, an engaged owner of high-quality, global companies which was founded by the Wallenberg family in 1916. For more information, please visit www.molnlycke.com.